Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Newly Diagnosed Multiple Myeloma
Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Ne
The combination of carfilzomib, lenalidomide, and low-dose dexamethasone has been shown to be highly active in patients with newly diagnosed multiple myeloma and provides rapid and deep responses, according to a presentation at the 2012 Annual Meeting of the American Society of Clinical Oncology. Extended treatment was well tolerated and resulted in improved depth of response, with a high stringent complete response rate and a significant proportion of patients without evidence of minimal residual disease.INTENDED AUDIENCE:
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with multiple myeloma.Activity Objectives:
After participating in this educational activity, participants should be better able to:
- Compare the efficacy and safety of regimens that contain an immunomodulatory agent and a proteasome inhibitor as initial treatment of newly diagnosed multiple myeloma (MM).
- Assess the response rates for pomalidomide in combination with low-dose dexamethasone in refractory MM patients unresponsive to transplantation.
Click Next to begin the activity.